'Outstanding Data': Mosunetuzumab in R/R Follicular Lymphoma

The investigational monoclonal antibody showed impressive activity in patients with follicular lymphoma that had relapsed or was refractory to a median of 3 prior lines of therapy.

Related Keywords

United States ,California ,Washington University ,Missouri ,Siteman Cancer Center ,American ,L Elizabeth Budde ,Brads Kahl , ,American Society Of Hematology ,Genentech ,American Society Of Hematology Annual Meeting ,Drug Administration ,Washington University School Of Medicine ,City Of Hope Comprehensive Cancer Center ,Hope Comprehensive Cancer Center ,American Society ,Medscape Medical News ,Washington University School ,Hematology Annual Meeting ,Non Hodgkins Lymphoma ,Follicular Lymphoma ,Hematology ,Lymphoma ,Malignant Lymphoma ,Biologic Therapy ,Monoclonal Antibody ,Etuximab ,Ituximab ,Refractory ,Immunomodulator ,Lenalidomide ,Us Food And Drug Administration ,Nited States Food And Drug Administration ,Fda ,Hospitals ,Inpatient Care ,Tolerance ,Cancer ,Alignant Neoplasia ,Arcinoma ,T Cell ,